GHK-Cu (copper peptide): the mechanism of action, step by step

What GHK is and where it comes from

GHK (glycyl-L-histidyl-L-lysine) is a tripeptide that Loren Pickart identified in human serum in 1973, as an activity that prolonged the survival of normal liver cells¹. According to his group's reviews, it is present in plasma, saliva and urine, and its plasma concentration falls from about 200 ng/mL at age 20 to about 80 ng/mL at age 60². Two findings suggest the body also generates it locally: the GHK sequence sits within the α2 chain of type I collagen, from which it could be released by proteolysis in a wound¹⁰, and breakdown of the matrix protein SPARC releases GHK and KGHK²⁰. This review focuses on mechanism; the critical analysis of the trials and the regulatory status are in GHK-Cu: four decades of papers, few trials, and the technical sheet is at GHK-Cu.

Step 1: copper as the starting point

The first proposed mechanism was copper transport. During its isolation, GHK co-eluted with nearly equimolar copper; the tripeptide forms complexes with copper(II) and increased uptake of the metal into cultured hepatoma cells³. Its binding site resembles the copper-transport site of albumin: at equimolar albumin and peptide, about 42% of the copper was bound to GHK⁴. By calorimetry, the conditional dissociation constant of the complex at pH 7.4 was 7.0 × 10⁻¹⁴ M, in a 1:1 ratio⁵.

Why does skin need copper? Reviews point out that copper is a cofactor of the lysyl oxidase family, the enzymes that cross-link collagen and elastin⁶. We found no study measuring lysyl oxidase activity with GHK-Cu as the sole agent; in a combined system (GHK-Cu as the copper source plus mRNA for the chaperone ATOX1), that enzyme's activity rose to 1.78 times control⁷. Superoxide dismutase (SOD) is similar: GHK-Cu increased SOD activity in macrophages and in mice with lung injury⁸, but the complex itself showed no significant SOD-like activity⁹. The effect looks indirect, acting on the cell, rather than an enzymatic action of its own.

Step 2: more matrix and balanced remodeling

The strongest mechanistic data concern the extracellular matrix, and almost all of them come from François-Xavier Maquart's laboratory in Reims:

• Collagen: in fibroblasts, synthesis rose from 10⁻¹² to 10⁻¹¹ M, peaking at 10⁻⁹ M, with no change in cell number¹⁰.
• Glycosaminoglycans: dose-dependent, biphasic increase, peaking between 10⁻⁹ and 10⁻⁸ M; mainly dermatan sulfate and heparan sulfate, with no effect on hyaluronic acid¹².
• In vivo: in rat wound chambers, more dry weight, DNA, protein, collagen and glycosaminoglycans; collagen stimulation was twice that of other proteins, with more type I and III collagen mRNA¹¹.
• Decorin: GHK-Cu increased mRNA for decorin, the proteoglycan that organizes collagen fibers, and decreased biglycan mRNA in rat wounds¹³.

Reviews from Pickart's group add elastin to that list¹⁶. The most interesting piece for remodeling is another: in dermal fibroblasts, GHK-Cu increased MMP-2 (an effect reproduced by copper alone, but not by copper-free GHK) and, at the same time, secretion of its inhibitors TIMP-1 and TIMP-2¹⁴. In ischemic rat wounds, by contrast, treated tissue had less MMP-2, MMP-9 and TNF-α than controls, and wound area shrank by 64.5% by day 13, versus 45.6% with vehicle¹⁵. The pattern is context-dependent modulation, not a simple increase or blockade of proteases.

Step 3: cells, vessels and inflammation

• Keratinocytes: in culture, the complex increased proliferation; in skin-equivalent models, it increased p63, PCNA and integrins α6 and β1¹⁷.
• Irradiated fibroblasts: at 10⁻⁹ M, they divided faster and produced more bFGF and VEGF than controls early after exposure¹⁸. In keloid fibroblasts, copper tripeptide reduced TGF-β1 secretion at 24 hours¹⁹.
• Vessels: SPARC-derived KGHK peptides stimulated angiogenesis in vivo; that activity did not depend on bound copper²⁰.
• Inflammation and oxidation: in macrophages and mice, lower reactive oxygen species, TNF-α and IL-6, through suppression of NF-κB p65 and p38 MAPK⁸. In vitro, GHK-Cu inhibited iron release from ferritin and the lipid peroxidation that depends on it⁹.

Step 4: the gene signature and the hair follicle

From 2010 a broader mechanism was proposed: modulation of gene expression. An independent team used the Broad Institute's Connectivity Map tool to find that GHK reversed the gene signature of emphysematous destruction (127 genes) and, in human fibroblasts, restored collagen I contraction and remodeling in cells from COPD patients²¹. Pickart's group later analyzed GHK's profiles in that database: they come from 2 tumor cell lines (PC3 and MCF7), and 31.2% of genes changed expression by 50% or more²²; their reviews cite at least 4,000 human genes². These are computational and cell-culture analyses: they generate hypotheses, but do not show an effect in a person's skin.

In the hair follicle, the most cited ex vivo data used a sister molecule, AHK-Cu (alanyl-histidyl-lysine-copper): at 10⁻¹² to 10⁻⁹ M it elongated cultured human follicles and stimulated proliferation of dermal papilla cells²³.

Every human study we could verify

We searched PubMed and the reference lists of the 2026 reviews⁶³⁷. These are the human studies with published results, with design, size, duration and comparator where the abstract reports them:

• Diabetic ulcers (1994): multicenter, randomized, evaluator-blinded, vehicle-controlled; GHK-Cu gel. Median area closure of 98.5% vs 60.8%, and, in plantar ulcers treated right after debridement, infections in 7% vs 34%²⁴.
• Venous ulcers (1992): randomized, evaluator-blinded, 86 patients; 0.4% copper tripeptide cream vs 1% silver sulfadiazine and placebo. No difference from placebo; silver sulfadiazine was superior²⁵.
• After CO2 laser (2006): randomized, 13 patients, 12 weeks; regimen with or without GHK-Cu. No objective differences in erythema or wrinkles; higher satisfaction with GHK-Cu (P = .04)²⁶.
• Sparse eyebrows (2026, conference proceedings): randomized, double-blind, placebo-controlled, split-face; 18 participants, 2% GHK-Cu serum twice daily for 12 weeks. Significant increase in hair count and diameter on the treated side²⁷.
• Androgenetic alopecia (2016): 45 men, 6 months, 5-aminolevulinic acid–GHK complex (no copper stated) vs placebo; hair-count increase of 52.6 and 71.5 vs 9.6²⁸.
• Androgenetic alopecia (2025): retrospective, 7 men, 5 monthly sessions of minoxidil, dutasteride and copper peptides by tattooing, no control group; median regrowth of 26.5%²⁹.
• Hair loss (2018): open-label, single-arm, 1,000 patients; intradermal injections of a formulation with growth factors and copper tripeptide-1, 8 sessions every 3 weeks; less shedding in 83% on the pull test³⁰.
• Multi-ingredient cosmetics (2024 and 2025): open-label, uncontrolled studies by a manufacturer, with copper tripeptide-1 among other actives: dandruff over 15 days³¹ and acne scars over 45 days³².

Only the first 4 are controlled and test GHK-Cu as the main agent. A randomized, double-blind phase 2 trial of a GHK-Cu gel versus vehicle in standardized acute wounds, with 60 estimated participants, is still recruiting³³. For its use in regenerative blends, see GLOW, KLOW and Wolverine blends.

How it reaches the dermis

Mechanism only matters if the molecule reaches its site of action. In dermatomed human skin, under infinite-dose conditions over 48 hours, 136.2 µg/cm² of copper applied as the tripeptide permeated and 82 µg/cm² was retained in the tissue; the method measured copper, not intact peptide³⁴. Through intact human skin, by contrast, almost no peptide or copper passed in 9 hours; after microneedle pretreatment, 134 nmol of peptide and 705 nmol of copper permeated, with no signs of irritation³⁵. A 2025 review concluded that metal complexation and hydrophobic modification increase GHK's permeability, and that microneedles deserve further study³⁶.

The limits, with the same precision

• Almost all of the mechanism is in vitro or animal: collagen, decorin, MMP/TIMP and angiogenesis data come from cultures and rats^1011131415.
• Few independent trials: a 2025 review noted "a surprising absence of clinical studies" with GHK-Cu and Pal-GHK³⁶.
• Concentrated authorship: about 35% of the primary literature includes Pickart or Anna Margolina (Skin Biology) as authors⁶; Pickart isolated the peptide and, according to that review, held commercial interests for decades⁶.
• The molecule is not always the same: AHK-Cu, copper-free GHK and multi-ingredient formulas are not equivalent to GHK-Cu²³²⁸³⁰, and the 2026 review warns that coordination state, speciation and stability vary with formulation³⁷.